Your partners in health.
Developing new life changing medicines.
WATER SOLUBLE SILDENAFIL CRYSTALS
VILYA'S technology allows us to deliver the drug any way we would like. Our Sildenafil is available as a pill, chewable, liquid, gel or intectable.
Our team that's making pharmaceuticals healther
CEO
(CHIEF EXECUTIVE OFFICER)
William Miller
Inventor of Villya's Technology
William is a visionary leader with extensive experience in international diplomacy, aerospace, and pharmaceutical innovation. He attended Indiana State University and began his distinguished career contracting at the U.S. Department of State, serving for nearly a decade on a Medevac team within the International Narcotics and Law Enforcement division across multiple U.S. Embassies overseas. This role allowed William to hone his diplomatic skills and build a robust network of international contacts.
Upon returning to the United States, William was recruited by SpaceX to contribute to the Dragon Project, playing an integral role in achieving critical milestones for the successful launch of U.S.-manufactured spacecraft with astronauts on board.
In his entrepreneurial journey, William founded S7LLC, a medical device company focused on importing and licensing rapid diagnostic tests for Schistosomiasis and COVID-19. He later transformed S7LLC into ICT International, where, as President, he expanded the company's offerings to 13 different rapid diagnostic tests for infectious diseases globally.
In his pursuit of innovation in the pharmaceutical industry, William founded Villya Pharmaceuticals, where he created and patented a groundbreaking drug to treat Female Genital Schistosomiasis (FGS) (approval US 10,857,151 B1). His achievements include the development of Liquid Praziquantel, a patent-pending formulation that makes the drug accessible for children by enhancing its solubility and bioavailability through Villya's patented carbohydrate loading technology. Villya has since patented 483 life-saving drugs, transforming them into water-soluble aggregates that are easily absorbed.
A pioneer of excellence, William played a crucial role in securing the U.S. patent office's approval for Erectile Dysfunction Therapeutics (US 12,115,222 B2) on October 15, 2024, covering five second-generation ED medications. In early 2024, he divested Villya’s intellectual property related to supplements and CBD patents to form Hythlayn Inc., which now boasts over 382 improved water-soluble supplements, including the CBD family.
William is the ideal leader for Villya Pharmaceuticals' future, with his unparalleled international connections, diplomacy skills, and a remarkable track record of managing government and private projects worth over $700 million.
This version of the bio presents William Miller's career in a coherent and professional manner, highlighting his leadership and achievements across different sectors.
CSO
(CHIEF SCIENTIFIC OFFICER)
Sreeshailam Aare
Ph.D Organic Chemistrey
